证券代码：002020 证券简称：京新药业 公告编号：2026010 浙江京新药业股份有限公司 第四期员工持股计划首次授予部分非交易过户完成公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"、"京新药业"）分别于 2025 年 9 月 29 日召开的第八届董事会第十八次会议和 2025 年 10 月 20 日召开的 2025 年第二次临时股东会审议通过了《关于公司<第四期员工持股计划（草案）>及其 摘要的议案》，同意公司实施第四期员工持股计划。具体内容详见公司披露于巨 潮资讯网（www.cninfo.com.cn）上的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，现将公 司第四期员工持股计划（以下简称"本员工持股计划"）的实施进展情况公告如 下： 一、本期员工持股计划的股票来源及数量 本员工持股计划的股票来源为公司回购专用证券账户已回购的京新药业 A 股普通股股票。 公司于 2025 年 1 月 8 日召开的第八届 ...

Group 1: Drivers of Excess Returns from Stock Buybacks - Stock buybacks are positively correlated with the buyback ratio, where higher buyback ratios lead to greater excess returns. The highest excess returns for companies with buyback ratios over 5% are 4.48% and 4.36% for the 5th and 4th groups, respectively, while other groups yield less than 1.5% [1][11] - The valuation logic of "stronger gets stronger" and "undervaluation recovery" exists post-buyback announcement. Companies with low valuation (1st group) show a significant excess return of 7.45%, while the highest and lowest valuation groups yield 3.32% and 2.11% excess returns, respectively, over 90 days post-announcement [1][13] Group 2: Recent Stock Buyback Activities - From January 12 to January 16, 2026, 16 companies with more than 10 institutional ratings announced buybacks, with Salted Fish (盐津铺子) being notable for a buyback ratio exceeding 1%. Proya (珀莱雅) is recommended for its low PE percentile over the past three years [2][17] - Salted Fish efficiently completed its buyback, demonstrating strong confidence in its value, with revenue of 4.427 billion and net profit of 605 million in the first three quarters of 2025. The company is upgrading its distribution channels and enhancing profitability [2][19] - Proya initiated its first buyback on January 15, 2026, repurchasing 230,800 shares with a total plan amounting to 80 million to 150 million. The company reported revenue of 7.098 billion and net profit of 1.026 billion in the first three quarters of 2025, with a gross margin of 73.69% [2][19] Group 3: Yearly Stock Buyback Overview - From January 16, 2025, to January 16, 2026, 28 companies with more than 10 institutional ratings announced buybacks, with notable mentions being Jian Sheng Group (健盛集团) and Jingxin Pharmaceutical (京新药业) for buyback ratios exceeding 5% [3][20] - Jian Sheng Group initiated a buyback plan in October 2025, using 150 million to 300 million in self-funds and loans, with a maximum buyback price of 14.69 per share. The company reported revenue of 1.886 billion and net profit of 309 million in the first three quarters of 2025, with a significant cash flow increase of 72.95% [3][23] - Jingxin Pharmaceutical started its buyback plan in January 2025, planning to use 350 million to 700 million in self-funds for employee stock ownership plans. The company reported revenue of 3.048 billion, a slight decline of 5.0%, and a net profit of 576 million, with a non-recurring net profit growth of 8.92% [3][23]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

证券日报网讯 1月15日，京新药业在互动平台回答投资者提问时表示，公司会依据相关法律法规及公司 信披管理制度，做好信息披露工作。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月15日，京新药业在互动平台回答投资者提问时表示，公司JX2201美国暂未开展临床试 验，具体进展敬请关注相关公告。 ...

格隆汇1月15日丨京新药业(002020.SZ)在互动平台表示，深圳巨烽主要提供医用显示模块解决方案，公 司会应用最新技术协助研发工作，但是在类人脑方面暂未有布局。 ...

（记者 张明双） 京新药业（002020.SZ）1月15日在投资者互动平台表示，公司JX2201美国暂未开展临床试验，具体进 展敬请关注相关公告。 每经AI快讯，有投资者在投资者互动平台提问：公司JX2201国内已进入I期临床，美国IND获批，是不 是意味着可以在美国开展临床试验了？是不是公司海外授权的目标公司是美国药企？ ...

Core Viewpoint - Jingxin Pharmaceutical announced plans to issue overseas listed shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to enhance its global strategy, international image, and overall competitiveness [1]. Group 1 - The company aims to deepen its globalization strategy [1] - The issuance of H-shares is part of the company's efforts to improve its international image [1] - The listing on the Hong Kong Stock Exchange is intended to increase the company's comprehensive competitiveness [1]

Summary of the Conference Call for Jinxin Pharmaceutical Industry Overview - Jinxin Pharmaceutical focuses on generic drugs, active pharmaceutical ingredients (APIs), and medical devices, with a strong presence in the CNS and cardiovascular sectors. The impact of centralized procurement has gradually diminished, allowing for stable growth in traditional pharmaceutical business [2][3][5]. Key Points Traditional Pharmaceutical Business - The traditional business includes generic drugs, APIs, and medical devices, with generics being the largest revenue contributor. The company has overcome the pressures from centralized procurement, and major products are expected to maintain steady growth [3][5]. - The integration of APIs and formulations provides cost advantages, and the acquisition of Shenzhen Jufeng has strengthened its position in the medical device market [2][5]. Innovative Drug Development - **Dazaxine (地达西尼)**: A new generation insomnia treatment that avoids safety issues associated with traditional benzodiazepines. It has shown rapid market uptake, with sales reaching 110 million RMB in the first three quarters of 2025, exceeding market expectations. It is expected to experience significant growth in 2026 and 2027 [2][6][8]. - **JX2,201**: A novel small molecule targeting lipid reduction, currently in phase II clinical trials. While it may not contribute significantly to short-term revenue, it has substantial business development (BD) potential and is expected to be a key driver of long-term growth [2][7]. Market Position and Competitive Landscape - Dazaxine competes with three major insomnia treatments, including those from Eisai and Shionogi. Its unique mechanism allows for rapid onset of action and minimal interaction with other medications, making it suitable for patients with multiple comorbidities [6][8]. - Jinxin's small molecule LPA innovation drug has a similar structure to Eli Lilly's drug, which is in phase III trials. If successful, it could enhance Jinxin's market position and BD potential [9]. Future Outlook - The company is expected to maintain steady growth in its traditional business due to the resolution of centralized procurement impacts. The rapid commercialization of Dazaxine and the promising outlook for the small molecule LPA drug contribute to a favorable investment profile [11]. - The potential for significant BD transactions for the LPA drug is highlighted, with upfront payments estimated between 100 to 200 million USD and total deals potentially reaching 2 billion USD [4][11]. Additional Insights - The differences between small molecule and small nucleic acid LPA-targeting drugs lie in their administration methods and mechanisms of action, with no significant efficacy differences reported so far [10]. - The company’s strategic focus on both traditional and innovative drug segments positions it well for future growth and investment opportunities [3][11].